Spectral Medical Inc. (TSX:EDT)
Canada · Delayed Price · Currency is CAD | Market Cap | 365.70M +78.4% |
| Revenue (ttm) | 2.71M +34.8% |
| Net Income | -41.70M |
| EPS | -0.15 |
| Shares Out | 292.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,340 |
| Average Volume | 31,807 |
| Open | 1.260 |
| Previous Close | 1.280 |
| Day's Range | 1.240 - 1.280 |
| 52-Week Range | 0.660 - 1.840 |
| Beta | 0.22 |
| RSI | 39.16 |
| Earnings Date | Mar 27, 2026 |
About Spectral Medical
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac prot... [Read more]
Financial Performance
In 2024, Spectral Medical's revenue was 2.29 million, an increase of 43.05% compared to the previous year's 1.60 million. Losses were -15.40 million, -1.66% less than in 2023.
Financial StatementsNews
Spectral Medical Provides Update on PMA Submission Timing for PMX-20R
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Inc. (EDT:CA) Discusses Year-End Update: FDA Filing Timeline, Tigris Trial Results, and Commercialization Readiness Transcript
Spectral Medical Inc. (EDT:CA) Discusses Year-End Update: FDA Filing Timeline, Tigris Trial Results, and Commercialization Readiness Transcript
Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Spectral Medical Announces Publication of EDEN Observational Study
New Study Strengthens Rationale for Spectral's PMX Therapy by Defining Endotoxic Septic Shock (ESS) as the Highest-Risk Patient Group New Study Strengthens Rationale for Spectral's PMX Therapy by Defi...
Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025
TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Spectral Medical Receives US$3 Million From Vantive
TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical and Vantive Announce Topline Results from Spectral's Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock
TORONTO, Ontario and DEERFIELD, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and sep...
Spectral Medical Announces Second Quarter and Provides Corporate Update
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus
TORONTO, July 04, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, to...
Spectral Medical Announces First Quarter and Provides Corporate Update
TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, to...
Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive
• Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • Company to ho...
Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update
TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Spectral Medical Provides November Tigris Trial Update
• 136 patients enrolled • Company to host Tigris Trial Update Call December 16, 2024 TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late...
Spectral Medical Announces Third Quarter Results and Provides Corporate Update
Tigris Trial Enrollment at 135 Patients Strengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment
Spectral Medical Provides October Tigris Trial Update
• 135 patients enrolled TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for se...
Spectral Medical Announces Second Quarter Results and Provides Corporate Update
Tigris Trial Enrollment Reaches 126 Patients Strengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spect...
Spectral Medical Provides July Tigris Trial Update
• 125 patients enrolled• Record July patient enrollment to start the second half of 2024
Spectral Medical Inc. Announces Change to Auditor
TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Provides June Tigris Trial Update
TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Inc. Announces Closing of Approximately C$8.5 Million Convertible Notes Financing
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF...
Spectral Medical Announces First Quarter Results and Provides Corporate Update
Tigris Trial Enrollment Reaches 106 Patients Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or...
Spectral Medical Inc. Announces C$8.5 Million Bought Deal Convertible Note Financing
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF...
Spectral Medical Provides April Tigris Trial Update
• 105 patients enrolled • April represents a record breaking month for patient enrollment TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),...